Project Grant K01DK144654
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $726,922 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Beckman Research Institute of the City of Hope. The grant will fund research examining the role of chromatin remodeling factors, specifically the protein JARID2, in modulating inflammatory processes that contribute to diabetic microvascular complications such as retinopathy and...
- This federal Project Grant award of $641,794 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant aims to elucidate the mechanisms that protect beta-cells from DNA damage during periods of growth and adaptation, in order to maintain beta-cell homeostasis and prevent the loss of functional beta-cells, a key factor in the development of type 1 and type 2...
- This federal Project Grant award of $444,867.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the UPR transducer XBP1 in pancreatic beta cell survival and function under metabolic stress. The research will use a novel mouse model to elucidate the pathological role of XBP1s in beta cell integrity under metabolic stress, in order to...
- This federal Project Grant award of $568,075.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award to Brigham Young University aims to determine the role of the transcription factor NR4A1 in the pathways that expand functional beta cell mass, which is critical for treating type 1 and type 2 diabetes. The research seeks to understand how NR4A1 is...
- This $847,746 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) supports research by the Beckman Research Institute of the City of Hope to investigate the role of the UPR transducer XBP1 in pancreatic beta cell survival and function under metabolic stress. The research aims to identify the "tilting point" of the unfolded protein response (UPR) under metabolic stress and explore its potential for therapeutic interventions for...
- This federal Project Grant award of $801,662, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research by the Scripps Research Institute to investigate the early phase of type 1 diabetes. The key objectives are to characterize the antigen-presenting cells associated with pancreatic islets during the pre-diabetic stage in mice, using advanced techniques...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $455,491 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of North Carolina at Chapel Hill. This grant will fund a 5-year research project to investigate the role of T follicular helper cells (Tfh) in regulating T cell-mediated autoimmunity in type 1 diabetes. The research aims to characterize changes in islet Tfh as the disease...
- The University of California, Davis received a $126,480 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to conduct research on the role of the signaling protein 14-3-3-z in regulating the crosstalk between pancreatic islet cells. The research aims to define a new pathway regulating 14-3-3-z expression in beta cells and investigate how this impacts alpha cell function and glucose-stimulated insulin secretion. This project is expected...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $621,794 Project Grant to Islex Therapeutics, LLC on August 1, 2025. The grant supports the preclinical development of a therapeutic antibody for treating type 1 diabetes (T1D), a chronic autoimmune disease affecting approximately 1.5 million Americans. The objective is to establish proof-of-principle for a humanized...
- This Project Grant award, with $1,331,148 in funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to investigate the mechanisms of islet cell compensation for beta-cell mass deficiency in type 2 diabetes. The research aims to determine the signaling pathways through which increased glucagon secretion from pancreatic alpha-cells helps preserve...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), through the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $153,554 Project Grant to the Beckman Research Institute of the City of Hope. This grant, awarded on September 15, 2025, supports research aimed at unveiling novel targets for type 1 diabetes therapy by investigating the functional heterogeneity of pancreatic alpha cells and their interactions with beta and delta cells. The project leverages innovative methodologies, particularly the use of human pancreatic tissue slices, to shed light on the complex regulatory mechanisms governing alpha cell behavior under normal and diabetic conditions. The research findings are expected to advance the understanding of alpha cell function and potentially lead to the development of new therapeutic interventions for type 1 diabetes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/18/25 | ||
| Not listed | $153.6k | 9/12/25 |